Prostate Cancer News and Research

Latest Prostate Cancer News and Research

CBC members, patient advocacy organizations offer support for PRIME Act

In a presentation today at the Congressional Black Caucus Foundation's Annual Legislative Conference Health Braintrust meeting, Faina Shtern, M.D., president and CEO of AdMeTech Foundation, unveiled overwhelming support from Congressional Black Caucus members and patient advocacy organizations for the Prostate Research, Imaging, and Men's Education Act of 2010.

18 Sep 2010

PCF applauds new prostate cancer legislation

As hundreds of prostate cancer researchers, advocates and supporters Advance on Washington this week and push for more progress in fighting the disease, the Prostate Cancer Foundation applauds the prostate cancer legislation introduced on Tuesday by Senator Jon Tester of Montana.

17 Sep 2010

HHS awards grant to develop patient-centered outcomes research

U.S. Department of Health and Human Services (HHS) Assistant Secretary for Health, Howard K. Koh, MD, MPH, today announced the award of more than $14 million to develop, implement, and test strategies to increase the adoption and dissemination of interventions based on patient-centered outcomes research among racial and ethnic minority populations.

16 Sep 2010

Johns Hopkins offers sources who can answer queries on prostrate cancer

September 19-25 is National Prostate Cancer Awareness Week. If you are planning a story on prostate cancer, a disease that's diagnosed in more than 200,000 American men each year, please consider calling on experts from the Johns Hopkins Brady Urological Institute.

16 Sep 2010

CINJ experts available for discussion during National Prostate Cancer Awareness Month

The Cancer Institute of New Jersey (CINJ) is making experts available to discuss the risks, treatments and prevention options surrounding prostate cancer during September, which is National Prostate Cancer Awareness Month. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

15 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010

Organizations issue five-point plan to accelerate research, discovery of effective prostate cancer treatments

With $3 billion spent on the over-treatment of prostate cancer each year, new discoveries are prompting the prostate cancer community to Advance on Washington the week of September 13 - 18. This initiative calls for renewed commitments to finding answers that will enable physicians to cure more and over-treat less. The nation's leading prostate cancer organizations today issued a five point plan, targeted to policymakers, to accelerate research and discovery of effective prostate cancer treatments.

15 Sep 2010

TNS NIPO study underlines need for wide-scale, reliable prostate cancer screening

A recent TNS NIPO survey, on behalf of the Dutch Association of Urology (NVU) and the European Association of Urology (EAU), showed that almost four out of 10 Dutch men of 50 years and older suffer, or have suffered, from urinary complaints. The same number of men also said in the same survey they are worried that they may have prostate cancer.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Researchers develop new blood test to predict prostate cancer risk

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.

15 Sep 2010

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals, Inc. today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile.

14 Sep 2010

Men with low PSA level does not benefit further treatment: Study

Men aged 55 to 74 years who have low baseline blood levels of prostate specific antigen (PSA) are not likely to benefit from further screening and treatment. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The aim of the study is to help physicians and patients weigh the pros and cons of prostate cancer screening and early detection.

13 Sep 2010

Measuring PSA levels effective in detecting prostate cancer: Study

A new multinational study suggests that regular blood testing to measure levels of prostate specific antigen (PSA) is more effective at detecting prostate cancer in men with a genetic predisposition to the disease.

13 Sep 2010

PCRI to host educational event on prostate cancer therapy

Dean Ornish MD, recognized for establishing the impact of diet on prostate cancer (and heart disease), along with over a dozen internationally recognized prostate cancer experts will meet with over 800 prostate cancer survivors and their significant others at the Los Angeles Marriott near LAX on September 11th and 12th to discuss the latest thinking on prostate cancer treatment.

13 Sep 2010

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

Pennsylvania Bio today issued a new report on cancer that details the research happening through Pennsylvania companies to develop new products to diagnose and treat cancer.

12 Sep 2010

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.

10 Sep 2010

Nucletron to present innovative cancer treatment during ESTRO29

Nucletron, a leading provider of state of the art radiotherapy solutions for cancer treatment, today announced a large number of exciting innovations for precise cancer treatment that will be in the spotlight during ESTRO29 in Barcelona. The company will be showcasing the latest developments in cancer treatment solutions for both brachytherapy and external beam.

10 Sep 2010

Experts advise men to maintain record of prostate specific antigen test results for risk detection

Experts at The University of Texas MD Anderson Cancer Center advise men to keep a record of their prostate specific antigen (PSA) test results to help determine if they are at increased risk for prostate cancer.

10 Sep 2010

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.

9 Sep 2010

Non-invasive test using patient's breath can detect cancer

A test using a patient's breath could be developed to detect lung, breast, bowel and prostate cancers, a team of scientists have discovered.While these results are only preliminary, the study published in the British Journal of Cancer today (Wednesday), found that sensors could distinguish between the breath of healthy patients and those who have cancer.

9 Sep 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

CBC members, patient advocacy organizations offer support for PRIME Act

PCF applauds new prostate cancer legislation

HHS awards grant to develop patient-centered outcomes research

Johns Hopkins offers sources who can answer queries on prostrate cancer

CINJ experts available for discussion during National Prostate Cancer Awareness Month

Phase II clinical trial shows GTx-758 reduces serum free testosterone

Organizations issue five-point plan to accelerate research, discovery of effective prostate cancer treatments

TNS NIPO study underlines need for wide-scale, reliable prostate cancer screening

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Researchers develop new blood test to predict prostate cancer risk

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Men with low PSA level does not benefit further treatment: Study

Measuring PSA levels effective in detecting prostate cancer: Study

PCRI to host educational event on prostate cancer therapy

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Nucletron to present innovative cancer treatment during ESTRO29

Experts advise men to maintain record of prostate specific antigen test results for risk detection

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Non-invasive test using patient's breath can detect cancer

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in